Raytheon awarded $71 million in Navy contracts for missile systems
DSS, Inc. (NYSE:DSS), a ten percent owner of Impact Biomedical Inc. (NASDAQ:IBO), has recently executed a series of stock transactions, according to a recent SEC filing. Impact Biomedical, currently valued at $57 million, has seen remarkable performance with a 531% return over the past week. InvestingPro analysis shows the stock’s RSI suggests overbought territory, with 12 additional exclusive insights available to subscribers. The company sold shares worth $249,408, with prices ranging from $2.90 to $4.68 per share. This significant divestiture reduced DSS’s holdings in Impact Biomedical to zero shares under the ownership of Sentinel Brokers Company, Inc., a majority-owned subsidiary of DSS.
In addition to the sales, DSS also purchased shares valued at $310, at a price of $1.55 per share, on March 20. Following these transactions, DSS continues to hold substantial shares in Impact Biomedical through its other subsidiaries, DSS BioHealth Security, Inc., DSS Securities, Inc., and DSS BlockChain Security, Inc.
In other recent news, Impact BioMedical Inc. announced the acquisition of Celios®, an air purification technology company, in an all-equity deal valued at approximately $1.15 million. This strategic move is intended to expand Impact BioMedical’s health and wellness portfolio and potentially increase its revenue. Celios® is recognized for its advanced air purification systems, which are protected by patents in the U.S. and other countries until 2043. The acquisition aligns with Impact BioMedical’s strategy to enhance its offerings in innovative health and wellness solutions.
Despite this development, Impact BioMedical has reported no significant changes in its business operations that could explain the recent volatility in its stock price. The company stated that there have been no material developments that would account for the unusual market activity, leaving investors and analysts without clear insights into the stock’s recent fluctuations. Impact BioMedical continues to focus on its mission of developing healthcare solutions while maintaining communication with its investors. The company has reminded stakeholders about the forward-looking nature of its public statements, which are subject to various uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.